Get the Daily Brief
Latest Biotech News
Roche pays $80M upfront for Hansoh ADC — deal worth up to $1.45B
Roche struck a global licensing deal with Hansoh Pharma, paying an $80 million upfront cash fee for rights to an early-stage antibody-drug conjugate targeting CDH17 in colorectal cancer. The...
Rani links with Chugai on oral delivery: pact worth up to $1.08B
Rani Therapeutics announced a strategic collaboration with Chugai to pair Rani’s oral biologic delivery capsule with a Chugai experimental antibody for a rare-disease indication, in a deal valued...
Pelage raises $120M series B to push hair-stem-cell therapy to phase III
Pelage Pharmaceuticals closed a $120 million Series B financing led by ARCH Venture Partners and GV to advance its hair follicle stem cell program PP405 toward Phase III testing. The funds will...
Adcytherix closes €105M series A to advance ADC candidate into clinic
Adcytherix SAS secured a €105 million (approximately $122 million) Series A to advance its lead antibody-drug conjugate program toward clinical development next year. The round positions the...
Tumor‑infiltrating Fusobacterium induces quiescence, blunts chemo response
Researchers at MD Anderson Cancer Center identified a mechanism by which tumor-infiltrating bacteria—principally Fusobacterium nucleatum—surround tumor epithelial cells and induce a reversible...
Enhertu into earlier disease — ADCs climb the treatment ladder
AstraZeneca and Daiichi Sankyo presented new data showing Enhertu (trastuzumab deruxtecan) produces substantive benefits when moved into earlier-stage breast cancer settings, signaling a tactical...
Roche’s oral SERD shows broad activity — giredestrant data reported
Roche disclosed phase 3 data from the evERA study showing its oral selective estrogen receptor degrader (SERD), giredestrant, improved progression-free survival compared with standard-of-care...
FDA names first nine national‑priority picks — review clock accelerated
The FDA selected the first nine recipients for its Commissioner’s National Priority Voucher (CNPV) pilot, allowing qualifying drug reviews to be fast‑tracked to a one- to two‑month window. The...
Grail’s Galleri shows improved specificity — new PATHFINDER evidence
Grail released updated PATHFINDER data from its large U.S. study showing improved positive predictive value for the Galleri multi‑cancer early detection blood test, strengthening the company’s...
Digital twins and ultra‑rapid WGS — AI meets clinical genomics
Sophia Genetics launched Sophia DDM Digital Twins, an AI‑powered research module that builds patient-specific computational replicas using multimodal clinical, imaging and genomic datasets to...
Licensing surge — Roche secures Hansoh ADC, Rani inks Chugai pact
Big‑ticket licensing deals dominated the therapeutics market this week as Roche paid an $80 million upfront to license Hansoh Pharma’s CDH17‑targeting ADC for colorectal cancer and announced...
Megafunding returns — Pelage and Adcytherix close nine‑figure rounds
Investor appetite for drug developers showed renewed strength as Pelage Pharmaceuticals closed a $120 million Series B to advance a hair‑follicle stem cell therapy (PP405) toward Phase III, and...
Tumor microenvironments reshape resistance — bacteria and surface 'pockets'
MD Anderson researchers reported that tumor‑infiltrating Fusobacterium nucleatum can induce reversible quiescence in epithelial cancer cells, impair immune detection and blunt chemotherapy...
Mixed EMA verdicts — CHMP recommends some U.S. approvals, rebuffs others
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) delivered a mixed slate of opinions: recommending two drugs already approved in the U.S. while issuing a...
Tumor‑on‑chip models accelerate CAR‑T research — new bioengineered platforms
Two seminal papers in Nature journals report microengineered tumor‑on‑chip systems that vascularize human tumor explants and permit controlled perfusion with immune cells to model CAR‑T cell...
Enhertu expands to early breast cancer: ESMO data show benefit
AstraZeneca and Daiichi Sankyo reported new data at ESMO showing Enhertu (trastuzumab deruxtecan) produces meaningful responses when used earlier in the breast cancer treatment pathway. Trial...
Roche’s oral SERD works in non‑mutant breast cancer — phase 3 readout
Roche presented detailed phase 3 results showing its oral selective estrogen receptor degrader (SERD), giredestrant, produced progression‑free survival gains in patients without ESR1 mutations and...
Grail tightens Galleri’s accuracy — PATHFINDER 2 readouts ahead of filing
Grail released large‑study results indicating its multi‑cancer blood test Galleri improved positive predictive value (PPV) in the PATHFINDER program, increasing the proportion of positive screens...
FDA awards nine national‑priority vouchers: reviews shortened to weeks
The U.S. Food and Drug Administration announced the first nine recipients of its Commissioner’s National Priority Voucher (CNPV) pilot program, giving selected sponsors the option of very rapid...
Fusobacterium induces tumor quiescence — bacteria blunt chemo response
Researchers at MD Anderson reported that tumor‑infiltrating Fusobacterium nucleatum can induce a reversible quiescent state in cancer epithelial cells, impairing immune detection and reducing...